A multicentre trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory AML or CML in blast crisis - Interim results.

被引：0
|
作者：
Hoechsmann, B
Doehner, H
Ganser, A
Heil, G
Denzlinger, C
Einsele, H
Duerk, H
Raghavachar, A
Hoelzer, D
Bergmann, L
机构：
[1] Univ Ulm, Ulm, Germany
[2] MHH, Hannover, Germany
[3] Univ Tubingen, Tubingen, Germany
[4] Sankt Marien Hosp, Hamm, Germany
[5] Klinikum Wuppertal, Wuppertal, Germany
[6] Univ Frankfurt, D-6000 Frankfurt, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4564
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [1] Combination of mitoxantrone, topotecan and cytarabine in patients with refractory or relapsed AML or CML in blast crisis.
    Hoechsmann, B
    Döhner, H
    Ganser, A
    Heil, G
    Einsele, H
    Raghavachar, A
    Hoelzer, D
    Bergmann, L
    BLOOD, 2000, 96 (11) : 325A - 325A
  • [2] A new combination therapy with topotecan, cytarabine and mitoxantrone in patients with refractory or relapsed acute myeloid leukemia or blast crisis of chronic myeloid leukemia.
    Höchsmann, B
    Griesshammer, M
    Bergmann, L
    BLOOD, 1999, 94 (10) : 230B - 230B
  • [3] MITOXANTRONE AND 5-AZACYTIDINE FOR REFRACTORY RELAPSED ANLL OR CML IN BLAST CRISIS - A LEUKEMIA INTERGROUP STUDY
    GOLDBERG, J
    GRYN, J
    RAZA, A
    BENNETT, J
    BROWMAN, G
    BRYANT, J
    GRUNWALD, H
    LARSON, R
    VOGLER, R
    PREISLER, H
    AMERICAN JOURNAL OF HEMATOLOGY, 1993, 43 (04) : 286 - 290
  • [4] Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.
    Castagnola, C
    Alessandrino, EP
    Pagnucco, G
    Bernasconi, P
    Lunghi, M
    Colombo, A
    Brusamolino, E
    Bonfichi, M
    Corso, A
    Lazzarino, M
    Bernasconi, C
    BLOOD, 2000, 96 (11) : 210B - 210B
  • [5] CLOFARABINE, CYTARABINE AND MITOXANTRONE FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA - INTERIM RESULTS OF A PROSPECTIVE PHASE 2 STUDY
    Gill, H.
    Ip, H. W.
    Yip, S. F.
    Kho, B.
    Lee, H.
    Mak, V.
    Lau, J.
    Lau, C. K.
    Lin, S. Y.
    Wong, R.
    Li, W.
    Kwong, Y. L.
    HAEMATOLOGICA, 2017, 102 : 677 - 677
  • [6] Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML
    Pardee, Timothy S.
    Isom, Scott
    Ellis, Leslie Renee
    Howard, Dianna S.
    Bhave, Rupali
    Manuel, Megan
    Dralle, Sarah
    Lyerly, Susan
    Powell, Bayard L.
    BLOOD, 2017, 130
  • [7] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [8] Phase II trial of arsenic trioxide (AS203) in patients (PTS) with relapsed/refractory acute myeloid leukemia (AML), blast crisis of CML, or myelodysplasia (MDS).
    Wiernik, PH
    Dutcher, JP
    Gallagher, R
    Caliendo, G
    Garl, S
    Paietta, E
    BLOOD, 1999, 94 (10) : 510A - 510A
  • [9] Interim results of a multicenter phase I/II trial of the combination of imatinib mesylate with mitoxantrone/etoposide and cytarabine in patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf, S
    Topaly, J
    Buss, EC
    Fischer, T
    Emmerich, B
    Gschaidmeier, H
    Hehlmann, R
    Ho, AD
    Hochhaus, A
    BLOOD, 2003, 102 (11) : 255B - 255B
  • [10] A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Godwin, J
    White, C
    Beltran, O
    Stiff, P
    BLOOD, 2000, 96 (11) : 214B - 214B
12345